Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells

Fonteneau, Jean-François; Larsson, Marie; Somersan, Selin; Sanders, Catherine J.; Münz, Christian; Kwok, William W.; Bhardwaj, Nina; Jotereau, Francine

doi:10.1016/s0022-1759(01)00477-x

Cited by 88 publications

(79 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Monocyte-derived dendritic cells (Mo-DC) were generated by culturing monocytes isolated from peripheral blood mononuclear cells (PBMCs) of healthy HLA-A2 ϩ donors as described (36). The presence of SPAS-1 peptide-specific CD8 ϩ T cells was determined by coculturing 1 ϫ 10 5 CD8 ϩ T cells with 5 ϫ 10 4 HLA-A2-expressing 721.221 B lymphoblastoid cells (A221) cells pulsed with the appropriate peptide.…”

Section: Bm-dc Vaccinations and Tumormentioning

confidence: 99%

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

Fassò¹,

Waitz

Hou

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

Section: Bm-dc Vaccinations and Tumormentioning

confidence: 99%

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

Fassò¹,

Waitz

Hou

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Polyclonal TIL were expanded in 96-well multiplates at 1000 TIL/well in the presence of irradiated feeder cells (1 ϫ 10 4 LAZ cells and 10 5 PBL/well), 1 g/ml PHA-L (Sigma-Aldrich), and rIL-2. TIL clones were derived by limiting dilution and then were expanded under the same culture conditions (27). The T cell clone C4-112 was derived from CD8 ϩ T cells present in the ascites of patient C4.…”

Section: ␥␦ T Lymphocytesmentioning

confidence: 99%

Vγ9Vδ2 T Cell Response to Colon Carcinoma Cells

Corvaisier

Moreau-Aubry

Viles

et al. 2005

The Journal of Immunology

Self Cite

185

149

View full text Add to dashboard Cite

During analysis of CD8 T cells derived from ascites of a colon cancer patient, we isolated a Vγ9Vδ2 T cell clone showing strong reactivity against autologous tumor cell lines. This clone killed a large fraction of allogeneic colon carcinoma and melanoma cell lines, but did not affect a normal colon cell line, colon fibroblasts, or melanocytes. Tumor cell recognition was TCR and NKG2D dependent and induced TNF-α and IFN-γ secretion by the clone; accordingly, tumor targets expressed several NKG2D ligands, such as MHC class I chain-related gene A and UL16-binding protein molecules. Colon tumor recognition by Vγ9Vδ2 T cells was highly dependent on isopentenyl pyrophosphate production and ICAM-1 expression by target cells. Finally, similar reactivity patterns against colon carcinoma cell lines were observed using polyclonal Vγ9Vδ2 T cells of various origins, and Vγ9Vδ2 lymphocytes were present in the majority of colon tumor samples studied. Together, these results suggest that Vγ9Vδ2 T cells contribute to the natural immune surveillance against colon cancers. Therefore, this study provides a strong rationale for the use of Vγ9Vδ2 T cell agonists in immunotherapies targeting colon tumors.

show abstract

“…1 T-cell clone culture HLA-A Ã 0201/MUC1(950-958)-or HLA-A Ã 0201/NY-ESO-1(157-165)-specific CD8 1 T-cell clones were obtained by limiting dilution and cultured as described previously [29]. Briefly, T-cell clones were restimulated with irradiated (35 Gy) feeder cells.…”

Section: Cd8mentioning

confidence: 99%

Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi

et al. 2012

Self Cite

View full text Add to dashboard Cite

Research into new treatments against malignant pleural mesothelioma (MPM) is of great interest, as this aggressive cancer is often resistant to conventional therapies. One potential strategy is the use of epigenetic drugs, such as 5-aza-2 0 -deoxycytidine (5-azaCdR), a DNAhypomethylating drug, and valproate (VPA), a histone deacetylase inhibitor (HDACi). Indeed, these drugs not only trigger MPM cell death, but also induce the expression of cancer testis antigens recognized by CD8 1 T cells, such as New York-esophageal cancer-1 (NY-ESO-1). The objective of this study was to assess effects of these drugs on the expression and recognition by CD8 1 T cells of Mucin1 (MUC1), a tumor-associated antigen that is overexpressed by MPM.MPM tumor cell lines were treated with epigenetic drugs, alone or in combination. MUC1 expression by MPM cells, and its recognition by a MUC1-specific CD8 1 T-cell clone, was downregulated by HDACi when used alone or in combination with 5-azaCdR. This effect was not due to a blocking of the HLA class I presentation pathway in treated MPM cells, as NY-ESO-1 induced by 5-azaCdR alone, or with VPA, was recognized by a NY-ESO-1-specific T-cell clone. This study suggests that the choice of tumor antigens could be critical for strategies combining epigenetic drugs with immunotherapy.

show abstract

Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells

Cited by 88 publications

References 26 publications

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

Vγ9Vδ2 T Cell Response to Colon Carcinoma Cells

Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi

Contact Info

Product

Resources

About

Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells

Cited by 88 publications

References 26 publications

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

Vγ9Vδ2 T Cell Response to Colon Carcinoma Cells

Downregulation of MUC1 expression and its recognition by CD8+ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi

Contact Info

Product

Resources

About

Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi